Virbel Guillaume, Le Fèvre Clara, Noël Georges, Antoni Delphine
Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033 Strasbourg, France.
Cancers (Basel). 2021 Jul 20;13(14):3623. doi: 10.3390/cancers13143623.
For several years, oligometastatic disease has represented an intermediate state between localized disease accessible to local treatment and multimetastatic disease requiring systemic therapy. The lung represents one of the most common metastatic locations. Stereotactic body radiation therapy (SBRT) appears to be the treatment of choice for these patients. There are few data defining the place of radiotherapy and reporting outcome after SBRT in lung metastases. This 5-year review aimed to determine areas of SBRT usefulness and methods for the management of pulmonary metastasis in oligometastatic patients. A search for articles on PubMed allowed selection of the most relevant studies. Eighteen articles were selected according to pre-established criteria for this purpose. The analysis concludes that SBRT is an effective and safe treatment in selected patients when the disease remains localized from one to three organs.
几年来,寡转移疾病一直代表着可进行局部治疗的局限性疾病与需要全身治疗的多转移疾病之间的一种中间状态。肺是最常见的转移部位之一。立体定向体部放射治疗(SBRT)似乎是这些患者的首选治疗方法。关于放疗在肺转移中的地位以及SBRT治疗后报告结果的数据很少。这项为期5年的综述旨在确定SBRT在寡转移患者肺转移管理中的有用领域和方法。在PubMed上搜索文章,从而筛选出最相关的研究。为此,根据预先设定的标准选择了18篇文章。分析得出结论,当疾病局限于1至3个器官时,SBRT对选定患者是一种有效且安全的治疗方法。